Theracryf - Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

Registrars:

Key Personnel

CEO: Huw Jones
CFO: Toni Hänninen
Interim Chairman: Susan (Sue) Foden
Independent Non-Executive Director: Alan Barge

Contact Details

Address: Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, Merseyside, United Kingdom
Phone:
Fax:
Website: http://www.theracryf.com/
Email:

Listings

ISIN: GB00BSVYN304
Sector: Pharma and Biotech, Pharma and Biotech
Main Indices: FTSE AIM All-Share